Understand Asthma Treatment Options: A Clinical Guide to Medicines and Ongoing Care
How asthma treatment is organized
Asthma treatment generally combines medicines that relieve symptoms, medicines that reduce airway inflammation, trigger management, monitoring, and a written action plan. Asthma medicines work mainly in two ways: quick-relief medicines open narrowed airways rapidly, while preventer medicines reduce swelling and irritation over time. The overall goals are symptom control, prevention of flare-ups, and limiting medicine-related adverse effects. Treatment decisions should be individualized according to symptoms, exacerbation risk, age, medical history, and inhaler technique. 1
A stepwise approach is commonly used, meaning treatment intensity can be adjusted when asthma is uncontrolled or when control has been sustained. Before escalating therapy, clinicians generally assess whether the diagnosis is correct, whether prescribed medicines are being taken as directed, whether the device is used correctly, and whether triggers or related conditions are contributing. Inhaled corticosteroid-containing treatment is considered a central component of long-term asthma management, rather than relying only on symptom relief. 2
Quick-relief and reliever medicines
Reliever inhalers are used when symptoms such as wheezing, coughing, chest tightness, or shortness of breath occur. Short-acting beta2-agonists, including salbutamol or albuterol in different national formularies, relax airway muscles quickly. They can improve breathing during acute bronchoconstriction, but they do not address the underlying airway inflammation. Frequent reliance on a short-acting reliever can indicate inadequate long-term control and should prompt a clinical review rather than automatic increases in use. 3
In Australia, anti-inflammatory reliever inhalers containing budesonide and formoterol are recommended for many people aged 12 and over instead of a blue puffer. Budesonide treats airway inflammation, while formoterol rapidly widens the airways, allowing one inhaler to address symptoms and part of the underlying cause. Whether this approach is suitable depends on the person’s age, diagnosis, treatment history, local guidance, and clinician’s written instructions. Medicines should not be changed without medical advice. 1
Preventer and controller treatment
Inhaled corticosteroids are the main anti-inflammatory preventer treatment for persistent asthma. Taken regularly at the prescribed dose, they reduce airway swelling and can lower the likelihood of exacerbations. Some people use an inhaled corticosteroid alone, while others use a combination inhaler containing an inhaled corticosteroid and a long-acting bronchodilator. The choice depends on symptom frequency, risk, response, age, and the person’s ability to use the selected device consistently. 2
Long-acting bronchodilators are generally used as part of an appropriate controller regimen and are not a substitute for anti-inflammatory treatment when an inhaled corticosteroid is indicated. Other controller options include leukotriene modifiers, which are taken orally, and selected additional medicines for people whose asthma remains difficult to control. Clinicians may step treatment up when symptoms or risks remain high and may consider stepping down after sustained control, but both changes require supervision. 4
Inhaler devices and technique
Most asthma medicines are inhaled because delivery through the lungs places treatment close to the affected airways. Available devices include metered-dose inhalers, dry-powder inhalers, soft-mist inhalers, and nebulized systems. Each requires a different breathing pattern, preparation method, and maintenance routine. A medication may appear ineffective when the principal problem is incorrect technique, so healthcare professionals commonly review technique after a new prescription, a treatment change, or continuing symptoms. 3
A spacer or holding chamber can assist delivery from an aerosolized metered-dose inhaler by improving deposition in the airways and reducing medicine remaining in the throat. Powder devices reduce the need to coordinate pressing and inhaling but require an adequate, forceful inhalation. Spacers should be washed and dried according to instructions to reduce contamination risk. Device selection therefore involves more than convenience and should account for coordination, inspiratory ability, age, dexterity, and routine adherence. 2
Options for uncontrolled or severe asthma
When asthma remains uncontrolled despite inhaled treatment, clinicians first reassess adherence, inhaler technique, ongoing exposures, and comorbidities. If additional treatment is justified, options can include long-acting bronchodilators, leukotriene modifiers, or other add-on medicines. Oral or intravenous corticosteroids may be used during significant exacerbations, but repeated systemic courses carry greater potential for adverse effects than inhaled treatment and should be minimized when clinically possible. 2
Biologic medicines are specialized injectable treatments for selected people with severe asthma, particularly when standard inhaled therapy is insufficient and testing indicates a relevant immune pathway. Examples of targets described in asthma care include immunoglobulin E and interleukin-related pathways. Eligibility is not based solely on symptom severity. Specialists may consider exacerbation history, inflammatory markers, allergy or eosinophilic features, current treatment, comorbidities, and response to previous therapies before selecting a biologic. 4
Nonmedication care, monitoring, and safety
Medication works alongside measures that reduce exposure to individual triggers. Relevant exposures can include tobacco smoke, air pollution, occupational irritants, allergens, respiratory infections, exercise-related triggers, and cold air, although triggers vary between individuals. Asthma care also includes education, regular assessment of symptom control, review of risk factors, and confirmation that the person understands the prescribed regimen. Allergy evaluation may be considered when symptoms appear linked to allergens, especially in children. 5
A written asthma action plan should identify daily medicines, signs that asthma is worsening, prescribed steps for changing treatment, and circumstances requiring urgent medical care. Severe shortness of breath, difficulty speaking, bluish lips, confusion, or poor response to a reliever are warning signs of a potentially dangerous attack. Emergency care is appropriate when these symptoms occur. A treatment plan should be reviewed when symptoms change, after an exacerbation, or whenever a medicine or inhaler device is changed. 6
Comparing the principal treatment categories
| Category | Primary role | Important limitation or consideration |
|---|---|---|
| Anti-inflammatory reliever | Rapid symptom relief combined with anti-inflammatory treatment in suitable plans | Use depends on age, local guidance, and a clinician’s instructions |
| Short-acting bronchodilator | Rapid relaxation of narrowed airway muscles | Does not treat airway inflammation |
| Inhaled corticosteroid controller | Long-term reduction of airway inflammation and exacerbation risk | Requires consistent use and correct inhaler technique |
| Combination controller | Pairs anti-inflammatory treatment with a long-acting bronchodilator | Selection and dosing must be individualized |
| Biologic therapy | Targets immune pathways in selected severe asthma cases | Requires specialist assessment and ongoing monitoring |
No single asthma treatment is appropriate for every patient. Differences in age, symptom pattern, lung function, triggers, pregnancy status, comorbidities, device skills, and previous exacerbations can change the balance of benefits and risks. Regulatory approvals and preferred treatment pathways also vary by country. The safest interpretation of treatment options is therefore a discussion framework for a qualified healthcare professional, not a substitute for diagnosis, prescribing, or an individualized action plan. 1
Sources
- National Asthma Council Australia, Asthma medicines
- Merck Manual Professional Edition, Pharmacologic Treatment of Asthma
- Canadian Lung Association, Asthma medications
- Merck Manual Consumer Version, Medications for Treating Asthma and Preventing Attacks
- Mayo Clinic, Childhood asthma, Diagnosis and treatment
- National Heart, Lung, and Blood Institute, Asthma treatment
Authored by 24Trendz team